RT Journal Article
T1 Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations
A1 Ariza, Javier
A1 Bosilkovski, Mile
A1 Cascio, Antonio
A1 Colmenero, Juan D.
A1 Corbel, Michael J.
A1 Falagas, Matthew E.
A1 Memish, Ziad A.
A1 Roushan, Mohammad Reza Hasanjani
A1 Rubinstein, Ethan
A1 Sipsas, Nikolaos V.
A1 Solera, Javier
A1 Young, Edward J.
A1 Pappas, Georgios
K1 Iraqi patients
K1 Cotrimoxazole
K1 Efficacy
K1 Metaanalysis
K1 Animales
K1 Antibacterianos
K1 Investigación Biomédica
K1 Brucelosis
K1 Países en Desarrollo
K1 Doxiciclina
K1 Combinación de Medicamentos
K1 Resistencia a Medicamentos
K1 Quimioterapia
K1 Fluoroquinolonas
K1 Gentamicinas
K1 Adhesión a Directriz
K1 Historia del Siglo XXI
K1 Humanos
K1 Recurrencia
K1 Estreptomicina
K1 Terminología como Asunto
K1 Resultado del Tratamiento
K1 Combinación Trimetoprim-Sulfametoxazol
K1 Salud Mundial
K1 Organización Mundial de la Salud
AB Summary PointsBrucellosis remains the commonest anthropozoonosis worldwide, and its treatment remains complex, requiring protracted administration of more than one antibiotic. In November 2006, a consensus meeting aimed at reaching a common specialist statement on the treatment of brucellosis was held in Ioannina, Greece under the auspices of the International Society of Chemotherapy and the Institute of Continuing Medical Education of Ioannina. The author panel suggests that the optimal treatment of uncomplicated brucellosis should be based on a six-week regimen of doxycycline combined either with streptomycin for 2–3 weeks, or rifampicin for six weeks. Gentamicin may be considered an acceptable alternative to streptomycin, while all other regimens/combinations should be considered second-line. The development of a common global therapeutic language for human brucellosis, and future, properly conducted clinical trials would definitely solve controversies regarding the disease.
PB Public Library of Science
SN 1549-1277
YR 2007
FD 2007-12
LK http://hdl.handle.net/10668/662
UL http://hdl.handle.net/10668/662
LA en
NO Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al. Perspectives for the treatment of brucellosis in the 21st century: The ioannina recommendations. Plos Med. 2007 Dec;4(12):1872-8
NO Policy Forum. Competing interests: ER has received research grants from Daiichi, Bayer, and Theravance and has served as a consultant to Pfizer, Theravance, Bayer, Wyeth, Rosetta, and BiondVax.
DS RISalud
RD Apr 20, 2025